In light of National Thyroid Awareness Month, GlobalData highlights that the lack of awareness around hypothyroidism (also known as ‘underactive thyroid’) is impacting diagnosis rates and limiting investment. The leading data and analytics company notes that only 14%* of Phase I-III clinical trials for hypothyroidism in the last five years were sponsored by pharma companies. […]

Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin. It is an X-linked recessive disorder mainly affecting males, that causes muscles to be fragile and easily damaged. DMD is progressive and most affected individuals require a wheelchair by adolescence. […]

The bipolar disorder pipeline is moderate in size containing agents in a range of different drug classes, including both tried and tested, and novel classes. However, it is unlikely that any product in the late-stage pipeline will be able to displace lithium as the gold standard of treatment, says GlobalData, a leading data and analytics […]

Less than 5%* of adults with overactive bladder (OAB) are currently managed with drug therapy due to a combination of low diagnosis rates and the poor risk-benefit ratio of available treatments, according to GlobalData. The leading data and analytics company notes that, despite this surprisingly low number and the clear need for new therapies, the […]

The FDA has yet to come to a conclusion on the approval of Lilly/Incyte’s JAK1/2 inhibitor Olumiant (baricitinib), AbbVie’s JAK 1 inhibitor Rinvoq (upadacitinib), and Pfizer’s, JAK 1 inhibitor Cibinqo (abrocitinib), the leading data and analytics company notes that competition will likely heighten once these JAK inhibitors become available. Ramla Salad, Pharma Analyst at GlobalData, […]